LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
04/08/2026
Voltar para busca
Dado oficial do USPTO
VALNEVA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
53
Atualização mais recente
04/08/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
31/05/2013
Data de registro
17/02/2015
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
09/05/2025
Última transação
04/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
Saint Herblain, FR
Examinador
BUONGIORNO, CHRISTOPHER L
Unidade examinadora
L10
Localização atual
TMEG LAW OFFICE 101
Titulares e representantes
Titulares
VALNEVA
VALNEVA
Representantes
Christina M. Licursi Wolf, Greenfield & Sacks, P.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals for use in industryscience and agricultureexcept fungicidesherbicidesinsecticides and parasiticides; molecules from biotechnologiesproteins in raw material for industrial usescientific or medical research; cells and cell lines for use in scientificlaboratorymedical research; nucleic acids for laboratory use; proteins in raw material form for scientific and medical research; recombinant proteins in raw material form for scientific and medical research; Biomedical compoundspeptide substrates and peptide antigens used in analyzing and detecting certain toxins for clinical or medical laboratory use; Biochemical preparations derived from blood serum used as growth promoters in tissue cultures and microbiological media; Biochemicalsantibodies and fragments thereof for in vitro scientific or research use; Chemicals for use in biotechnological product development; Cultures of microorganisms other than for medical and veterinary use; Biological preparations and bacteriological preparations for use in cell cultures other than for medical or veterinary use
Classe 5
Pharmaceuticals for human and veterinary use for the treatment of autoimmune diseasesinflammationcancerinfectious diseasesdiseases of the central nervous systemcardiovascular diseasesneurodegenerative and chronic diseases; antibodies and fragments thereof for use in disease testing; cell culturesmicroorganisms and viruses for medical and veterinary use; diagnostic agents for medicalpharmaceutical and veterinary use; cells for medical or clinical use; culture media for cultivating microorganism cells for medical and veterinary use; adjuvants for medical or and veterinary use; pharmaceutical and veterinary preparations for medicalpharmaceutical and veterinary usepreparations of encapsulated cells which release antibodiesliving cells and microorganismsvaccinesviral vectorsproteinspeptidesenzymesnucleic acids or pharmaceutically active compounds for the treatment of cancerauto-immune disordersinfectious diseasesinflammatory diseasesneurological and genetic disordersbowel diseasesdigestion problems
Classe 42
Scientific research services for medical purposes in the fields of autoimmune diseasesinflammationcancerinfectious diseasesdiseases of the central nervous systemcardiovascular diseasesneurodegenerative and chronic diseases; scientific research for medicalpharmaceutical and veterinary purposes in the fields of autoimmune diseasesinflammationcancerinfectious diseasesdiseases of the central nervous systemcardiovascular diseasesneurodegenerative and chronic diseases; scientific researchin particularin the fields of biologycellular and molecular biologybiotechnologybacteriologyimmunologygeneticsmedicinepharmacologyvirologychemistry; scientific research relating to vaccinesantibiotics and immunological products for human and veterinary use; research and development of new products for others; testinganalysisevaluation of the goods of others to assure compliance with industry standards in the scientificmedical and veterinary fields; development and design of laboratory instruments for scientific and industrial researchin particularto obtain and prepare cellscell linesvirusesproteinsanimal and human materials; development of vaccinesantibiotics and immunological products for human and veterinary use; scientific and technological servicesdiagnostic and prognostic analyses in the fields of cellscell linesanimal and human materialsmicroorganismsmolecules for scientific purposes; scientific researchpreparation of scientific experts opinions reports
Publicações
Histórico de despachos e eventos da marca no USPTO.
53 publicações encontradas
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
09/07/2026
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
09/05/2025
71AG
REGISTERED-SEC.71 ACCEPTED
09/05/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/05/2025
ES71
TEAS SECTION 71 RECEIVED
27/12/2024
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
22/05/2024
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
25/04/2024
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
25/02/2024
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
17/02/2024
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
17/02/2024
RNWL
INTERNATIONAL REGISTRATION RENEWED
07/04/2023
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
03/11/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
15/10/2022
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
01/10/2022
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
30/11/2020
C75A
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
30/11/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
24/11/2020
ES75
TEAS SECTION 71 & 15 RECEIVED
08/07/2020
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
17/02/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
26/09/2019
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
13/12/2018
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
22/12/2016
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
31/07/2015
FICS
FINAL DISPOSITION NOTICE SENT TO IB
29/06/2015
FIMP
FINAL DISPOSITION PROCESSED
29/06/2015
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
17/05/2015
R.PR
REGISTERED-PRINCIPAL REGISTER
17/02/2015
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/12/2014
PUBO
PUBLISHED FOR OPPOSITION
02/12/2014
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/11/2014
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
29/10/2014
ALIE
ASSIGNED TO LIE
28/10/2014
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/10/2014
XAEC
EXAMINER'S AMENDMENT ENTERED
09/10/2014
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/10/2014
GNEA
EXAMINERS AMENDMENT E-MAILED
09/10/2014
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/10/2014
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
24/04/2014
GNFR
FINAL REFUSAL E-MAILED
24/04/2014
CNFR
FINAL REFUSAL WRITTEN
24/04/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/04/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/04/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/04/2014
RFNT
REFUSAL PROCESSED BY IB
10/12/2013
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
20/11/2013
RFRR
REFUSAL PROCESSED BY MPU
20/11/2013
MAFR
APPLICATION FILING RECEIPT MAILED
19/11/2013
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
16/11/2013
CNRT
NON-FINAL ACTION WRITTEN
15/11/2013
DOCK
ASSIGNED TO EXAMINER
13/11/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
13/11/2013
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/11/2013
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VALNEVA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.